doi:10.1016/j.mrgentox.2005.01.013
Copyright © 2005 Published by Elsevier B.V.
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration
V. Koneti Raoa, Turid Knutsena, Thomas Rieda, Darawalee Wangsaa, Bernard Mike Flynnb, Gregory Langhamc, Merrill J. Egorind, Diane Colea, Frank Balisa, Seth M. Steinberga, Susan Batesa and Tito Fojoa,
, 
aCenter for Cancer Research, National Cancer Institute, NIH, Building 10, Rm 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA
bVeterinary Medicine and Resource Branch, NIMH/NIH, Bethesda, MD 20892, USA
cNCI/Division of Laboratory Animals, NCI, NIH, Bethesda, MD 20892, USA
dUniversity of Pittsburgh Cancer Center, Pittsburgh, PA 15213, USA
Received 8 April 2004;
revised 10 December 2004;
accepted 26 January 2005.
Available online 27 April 2005.
References and further reading may be available for this article. To view references and further reading you must
purchase this article.
Abstract
We utilized a non-human primate model, the rhesus monkey (Macaca mulatta), to quantitate the extent of chromosomal damage in bone marrow cells following chemotherapy. Thiotepa, etoposide, and paclitaxel were chosen as the chemotherapy agents due to their distinct mechanisms of action. Chromosomal aberrations were quantitated using traditional Giemsa stain. We sought to evaluate the extent to which genotoxicity was dependent on the schedule of administration by giving chemotherapy as either a bolus or a 96 h continuous infusion. Neutropenia and areas under the concentration curve (AUCs) were monitored to ensure comparable cytotoxicity and dose administered. At least 100 metaphases were scored in each marrow sample by an investigator unaware of the treatment history of the animals. All three drugs produced a statistically significant higher percentage of abnormal metaphases following bolus chemotherapy (p < 0.0001, p = 0.0015 and p < 0.0001 for thiotepa, etoposide and paclitaxel, respectively). We conclude that infusional administration of thiotepa, etoposide and paclitaxel is less genotoxic to normal bone marrow cells than is bolus administration. These results suggest infusional regimens may be considered where there are concerns about long-term genotoxic sequelae, including secondary cancer, teratogenicity, or possibly the development of drug resistance. We believe this approach provides a reproducible model in which drugs and eventually, regimens can be compared.
Keywords: Drug resistance; Chromosomal damage; Genotoxicity; Secondary malignancies; CIV chemotherapy
Abbreviations: AUCs, areas under the concentration versus time curve; CIV, Continuous intravenous infusion
Fig. 1. Spectral karyotyping (SKY) using human paints in rhesus monkey metaphases (42,XY). Apparent translocations at monkey chromosomes 2, 7 and 13 are due to repackaging of chromosomal contents from counterparts in human chromosomes 2, 14, 15, 21 and 22. Human chromosome 2 exists as two chromosomes (i.e. Chromosomes 9 and 15) in a rhesus monkey metaphase.
Fig. 3. Nomogram used for calculation of dose of chemotherapy agents in non-human primate models.
Fig. 4. Neutrophil counts obtained for the animals on study. (A) Neutrophil counts in the five animals receiving paclitaxel. Pre-treatment values obtained prior to the bolus administration (pre-bolus) or prior to the start of the infusion (pre-infusion) are compared with the lowest count recorded after administration of chemotherapy for that cycle (Bolus Nadir and Infusion Nadir). Nadir values bolus were 120, 107, 68, 685, and 645. Nadir values for infusion were 24, 549, 668, 1880, and 151. (B) Neutrophil counts for the group of animals receiving each drug.
Fig. 5. Area under the concentration curve (AUC) obtained for the animals on study. (A) AUCs in the five animals receiving thiotepa. Values calculated after bolus drug administration are compared with those calculated following infusional administration. (B) AUCs for the group of animals receiving each drug. The vertical line represents the mean value, while the box delineates the standard error. Each animal is identified by a different symbol.
Fig. 6. Examples of chromosomal damage scored in metaphase spreads following Giemsa staining. Arrows in the individual panels identify the different cytogenetic abnormalities. Panel A (normal); panel B (dicentric); panel C (chromatic fragment); panel D (complex aberration showing breaks and fragments); panel E (rings); panel F (multiple breakages and fragments). Representative examples of breaks, fragments, rings, gaps and complex aberrations are shown in the figure.
Fig. 7. Tabulation of percent abnormal metaphases found in the bone marrow sample from each individual animal. For each drug, the panel on the left demonstrates the results obtained when metaphases were scored in samples harvested directly after bone marrow aspiration. The panel on the right summarizes the data examining metaphases harvested from samples cultured in staphylococcal mitogen for 96 h.
Fig. 8. Comparison of abnormal metaphases tabulated both in the direct and the mitogen-stimulated samples. The statistical analysis of the results is summarized in the table at the bottom of the figure. All results were analyzed using an exact stratified Cochran-Armitage test.
Table 1.
Abnormal metaphases following chemotherapy exposure

Table 2.
Example of qualitative and quantitative aberrations seen following etoposide chemotherapy
